Clinical Trial Update: GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for GVD±R regimen in ASCT-eligible patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• GVD±R regimen

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: UNKNOWN